We herein provide evidence that AKT is frequently phosphorylated and exclusively augmented in native leukemia samples compared to physiologic mononuclear cells, making the PI3K/AKT pathway an attractive target in the treatment of acute leukemia. The gene discussed is AKT1; the disease is leukemia.